Research and Markets (http://www.researchandmarkets.com/research/a35234/pricing_and_reimbu)
has announced the addition of Decision Resources, Inc.'s new report "Pricing
and Reimbursement of Targeted Cancer Therapies" to their offering.
“Pricing
and Reimbursement of Targeted Cancer Therapies”
Given the life-threatening nature of cancer and the effectiveness and
tolerability of many targeted oncology drugs, healthcare payers have
typically been willing to provide generous coverage of these therapies.
However, the steady increase in spending on these agents is forcing
governments and private health insurers to reassess their reimbursement
strategies for cancer therapies. In an increasingly cost-conscious
environment, pharmaceutical companies must find new ways to justify the
cost of high-priced targeted therapies. This report reviews key trends
in seven major markets and includes valuable insights from a new survey
of 224 U.S. oncologists.
Questions Answered in This Report:
-
Healthcare payers around the world have very different approaches to
cost sharing for targeted cancer therapies. In the United States, how
do commercial and Medicare health plans differ in their cost-sharing
strategies? To what extent are European and Japanese patients required
to contribute to their treatment costs? What impact does cost sharing
have on patient access to targeted therapies?
-
In many markets, cancer therapy is administered primarily in
hospitals. How do some governments seek to control the use of
high-priced cancer therapies by limiting the use of these drugs to the
hospital setting or requiring an initial diagnosis by a hospital-based
specialist? What are the implications of the growth of prospective
payment systems (i.e., reimbursement based on diagnosis-related
groups) for funding of innovative cancer therapies?
-
Health technology assessment (HTA) will play an increasingly important
role in reimbursement decision making for targeted cancer therapies
and other high-priced medicines. How has the United Kingdom's National
Institute for Health and Clinical Excellence (NICE) pioneered the use
of HTA in making coverage decisions for cancer drugs? What actions are
payers in other countries taking to include HTA in their decision
making?
-
Faced with growing payer resistance to the relatively high prices of
targeted cancer therapies, drug manufacturers must devise new ways to
demonstrate that their products offer good value for money. What role
can companion diagnostics play in making the economic case for
targeted therapies? How are payers and pharmaceutical companies using
conditional reimbursement to improve patient access to oncology drugs?
Scope: